{"id":6556,"date":"2024-01-24T11:22:03","date_gmt":"2024-01-24T03:22:03","guid":{"rendered":"https:\/\/www.umtradings.com\/?p=6473"},"modified":"2024-01-26T08:36:39","modified_gmt":"2024-01-26T08:36:39","slug":"johnson-johnson-exceeds-quarterly-sales-expectations-maintains-outlook","status":"publish","type":"post","link":"https:\/\/www.umtradings.com\/vn\/johnson-johnson-exceeds-quarterly-sales-expectations-maintains-outlook\/","title":{"rendered":"Johnson &amp; Johnson Exceeds Quarterly Sales Expectations, Maintains Outlook\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Johnson &amp; Johnson (JNJ.US) reported fourth-quarter results that surpassed analyst expectations. The company posted sales of $21.40 billion and net income of $4.13 billion for the fourth quarter of 2023. On a per-share basis, net earnings were $1.70 compared to $1.22 in the same quarter a year ago when net income was $3.23 billion. Excluding one-time items, the company&#8217;s adjusted earnings per share amounted to $2.29 for the most recent quarter.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Following the spinoff of its former consumer products division, Kenvue, Johnson &amp; Johnson now operates through two business segments: Innovative Medicine, comprised of its pharmaceuticals division, and MedTech, representing its medical devices. Innovative Medicine revenue grew 4.2% to $13.7 billion during the quarter, while MedTech sales surged 13.3% to $7.7 billion.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">J&amp;J progressed in obtaining approvals for several new treatments, including its Balversa drug for bladder cancer. However, the company&#8217;s lucrative Stelara medication faces mounting competition in Europe as early as mid-2024. During an investor call, CEO Joaquin Duato stated that J&amp;J is pursuing acquisitions and is open to considering &#8220;many types of deals.&#8221;&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Johnson &amp; Johnson&#8217;s full-year 2024 guidance is unchanged from its December forecasts. The company projects operational sales growth of 5-6%, amounting to $88.2-$89 billion. For earnings, J&amp;J forecasts adjusted EPS of $10.55-$10.75, reflecting a 6.4-8.4% increase over last year. This EPS guidance aligns with the Wall Street consensus of $10.68.\u00a0<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img decoding=\"async\" src=\"https:\/\/www.umtradings.com\/vn\/wp-content\/uploads\/sites\/16\/2024\/01\/1-16.jpg\" alt=\"\" class=\"wp-image-6474\" \/><\/figure>\n<\/div>\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><em>(Johnson &amp; Johnson Stock Performance Monthly Chart)\u00a0<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Disclaimer&nbsp;&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Comments, news, research, analysis, price, and all information contained in the article only serve as general information for readers and do not suggest any advice. Ultima Markets has taken reasonable measures to provide up-to-date information, but cannot guarantee accuracy, and may modify without notice. Ultima Markets will not be responsible for any loss incurred due to the application of the information provided.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (JNJ.US) reported fourth-quarter results that surpassed analyst expectations. The company posted sales of $21.40 billion and net income of $4.13 billion for the fourth quarter of 2023. On a per-share basis, net earnings were $1.70 compared to $1.22 in the same quarter a year ago when net income was $3.23 billion. Excluding [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":6586,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2,3],"tags":[120,121],"class_list":["post-6556","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market_news","category-latest","tag-jnj-us","tag-johnson-johnson"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/posts\/6556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/comments?post=6556"}],"version-history":[{"count":0,"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/posts\/6556\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/media\/6586"}],"wp:attachment":[{"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/media?parent=6556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/categories?post=6556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.umtradings.com\/vn\/wp-json\/wp\/v2\/tags?post=6556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}